Eligible patients ( with adequate stem-cell harvest ) were randomly assigned ( 1:1 ) , using an automated telephone randomisation line , to either high-dose melphalan 200 mg/m ( 2 ) plus salvage ASCT or oral cyclophosphamide ( 400mg/m ( 2 ) per week for 12 weeks ) .